Advancing Clinically Validated Platform Toward Commercialization This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential of the FORCE platform and its conjugates, the therapeutic potential of zeleciment basivarsen (z-basivarsen, also known as DYN ...

Core Insights - Dyne Therapeutics has appointed Erick J. Lucera as the new Chief Financial Officer (CFO), effective March 31, 2025, bringing over 30 years of experience in the life sciences industry [1][2] - Lucera's expertise in financial strategy and capital allocation is expected to be crucial for advancing Dyne's late-stage clinical programs for DM1 and DMD towards potential regulatory approvals [2] Company Overview - Dyne Therapeutics focuses on developing innovative therapeutics for genetically driven neuromuscular diseases, utilizing its FORCE™ platform to create targeted treatments for muscle and the central nervous system [3] - The company has a broad pipeline that includes clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [3]